Abatacept as maintenance therapy in kidney transplantation: a retrospective comparative study
Charlotte Uro-Coste, Inès Ramos, Aurélien Tiple, Marine Freist, Claire Chatron, Alba Atenza, Jimmy Garraud, Clarisse Grèze, Carole Philipponnet, Paul Rouzaire, Anne-elisabeth Heng, Cyril Garrouste · 2026
Read Abatacept as maintenance therapy in kidney transplantation: a retrospective comparative study by Charlotte Uro-Coste, Inès Ramos, Aurélien Tiple, Marine Freist, Claire Chatron, Alba Atenza, Jimmy Garraud, Clarisse Grèze, Carole Philipponnet, Paul Rouzaire, Anne-elisabeth Heng, Cyril Garrouste (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13616798.txt.
Description
Charlotte Uro-Coste and co-authors compare two related immune drugs as upkeep therapy after kidney transplant. Their 2026 study reviews patients switched to one drug or the other from 2017 to 2023. The better-known drug is given by vein and faces supply gaps, which spurs interest in its cousin.
Seventy-four patients took part, split unevenly between the two drugs. Rejection within a year of the switch hit about one patient in ten in both groups. Rates of viral and opportunistic infections also matched. The authors judge the lesser-used drug acceptably safe by comparison. They suggest it as a backup when supply fails, vein access is poor, or more patient autonomy is sought, pending larger trials.
Catalog record
| CREATOR | Charlotte Uro-Coste, Inès Ramos, Aurélien Tiple, Marine Freist, Claire Chatron, Alba Atenza, Jimmy Garraud, Clarisse Grèze, Carole Philipponnet, Paul Rouzaire, Anne-elisabeth Heng, Cyril Garrouste |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |